Baseline characteristics of patients with steroid-refractory or -resistant pneumonitis
| No (%) | |
| No of patients | 26 |
| Median age, years (range) | 67 (52–79) |
| Female sex | 9 (34.6) |
| BMI, median (range) | 26.1 (21.3–−38.5) |
| Smoking status | |
| Former | 22 (84.6) |
| Never | 4 (15.4) |
| Pulmonary history* | |
| No | 19 (73.1) |
| Yes | 7 (26.9) |
| Primary malignancy | |
| NSCLC | 8 (30.8) |
| Malignant melanoma | 4 (15.4) |
| Renal cell carcinoma | 4 (15.4) |
| Sarcoma | 2 (7.7) |
| Head and neck squamous cell cancer | 2 (7.7) |
| Bladder carcinoma | 1 (3.8) |
| Colorectal carcinoma | 1 (3.8) |
| Esophageal squamous cell cancer | 1 (3.8) |
| Multiple myeloma | 1 (3.8) |
| Prostate cancer | 1 (3.8) |
| SCLC | 1 (3.8) |
| Line of therapy | |
| 1 | 9 (34.6) |
| 2 | 9 (34.6) |
| ≥3 | 8 (30.8) |
| Prior chest radiation | |
| No | 17 (65.4) |
| Yes | 9 (34.6) |
| Causative checkpoint inhibitor agent | |
| PD1 | 16 (61.5) |
| PDL1 | 3 (11.5) |
| CTLA4 | 1 (3.8) |
| Combination | 6 (23.1) |
*Asthma, COPD, OSA, bronchiectasis, ILD, history of pneumonitis, pulmonary embolism, pleural effusion.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung diseas; NSCLC, non-small cell lung cancer; OSA, obstructive sleep apnea.